Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

BridgeBio Pharma (BBIO) Income from Continuing Operations (2019 - 2025)

BridgeBio Pharma's Income from Continuing Operations history spans 7 years, with the latest figure at 194635000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 20.24% year-over-year to 194635000.0; the TTM value through Dec 2025 reached 666575000.0, down 32.55%, while the annual FY2025 figure was 732938000.0, 34.89% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 194635000.0 at BridgeBio Pharma, down from 149154000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 19053000.0 in Q1 2024 and bottomed at 244019000.0 in Q4 2024.
  • The 5-year median for Income from Continuing Operations is 161255500.0 (2021), against an average of 152372050.0.
  • The largest annual shift saw Income from Continuing Operations skyrocketed 86.59% in 2024 before it plummeted 640.71% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 180566000.0 in 2021, then rose by 19.62% to 145130000.0 in 2022, then plummeted by 32.37% to 192106000.0 in 2023, then dropped by 27.02% to 244019000.0 in 2024, then rose by 20.24% to 194635000.0 in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Income from Continuing Operations are 194635000.0 (Q4 2025), 149154000.0 (Q3 2025), and 181658000.0 (Q2 2025).